EarningsQ2 2026 Earnings Report
DE:EP3 Q2 2026 EPS Results
Actual EPS€0.08
Consensus EPS-€0.24
Beat/MissBeat by +€0.32
One Year Ago EPS-€0.23
DE:EP3 Q2 2026 Revenue Results
Actual Revenue€27.34M
Expected Revenue€25.97M
Beat/MissBeat by +€1.37M
YoY Revenue Growth-1.93%
Earnings Announcement Details
QuarterQ2 2026
Date08/05/2026
TimeAfter Close
Conference CallWednesday, August 5, 2026
DE:EP3 Upcoming Earnings
Orasure Technologies's next earnings date is estimated for November 10, 2026, based on past reporting schedules.
Q2 2026 Earnings Call Audio
DE:EP3 Q2 2026 Earnings Call
0:00 / 0:00
Q2 2026 Earnings Slide Deck
No slide deck is available for this earnings event.
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
The call presents a cautiously positive picture: the company delivered sequential revenue growth (9.7%), segment recoveries (Diagnostics +14.7% and SMS +9.0% sequentially), margin expansion (+120 bps GAAP gross margin) and achieved important regulatory milestones (Colli‑Pee FDA clearance and Ebola 2.0 EUA). The primary setback is the withdrawal and delay of the IntelliQ CT/NG FDA submission, alongside a non‑GAAP operating loss ($14.7M) and negative operating cash flow (‑$9.9M) this quarter. Strong cash ($161M), zero debt, insourcing and cost discipline, and clear launch plans temper the impact of the IntelliQ delay and one‑time G&A items; management reiterates revenue growth for 2026 and expects operating cash flow breakeven entering 2027.Company Guidance
Revenue Growth and Guidance
Total revenue of $30.6M in Q2 2026, exceeding guidance and growing 9.7% sequentially; Q3 2026 revenue guidance of $29.5M–$32.5M.
Diagnostics Segment Strength
Diagnostics revenue of $19.4M in Q2, with sequential growth of 14.7%; U.S. revenue exceeded international in the quarter and syphilis and BioMedomics (SickleSCAN) contributed to strength.
Sample Management Solutions (SMS) Recovery
SMS revenue of $9.9M in Q2, up 9.0% sequentially; sequential SMS improvement and anticipated contribution from Colli‑Pee support confidence in long‑term SMS growth.
Gross Margin Expansion and Operational Efficiencies
GAAP gross margin improved 120 basis points sequentially to 43.5% (from 42.3%); non‑GAAP gross margin increased to 44.2% from 43.4% (up 80 bps). Margin expansion driven by lower scrap and operational efficiencies.
Product and Regulatory Milestones
FDA clearance of Colli‑Pee urine collection kit (Colli‑Pee Dx) for 8 STI indications on Roche cobas platform; FDA EUA for OraQuick Ebola 2.0 rapid antigen test detecting all 4 human Ebola species, including Bundibugyo.
International Commercial Progress and Localization
Progress on nearshoring (in‑country assembly for OraQuick HIV self‑test), deeper public health partnerships across Africa/Latin America, and SickleSCAN integration with 2026 revenue growing 2x the 2025 pace.
Balance Sheet Strength
Cash & equivalents of $161M at quarter end and zero debt; returned $22M via share repurchases (7.7M shares, ~10% of outstanding) and used ~55% of $40M authorization, while pausing further buybacks to preserve flexibility.
Expense Discipline and R&D Taper
R&D expense declined sequentially and year‑over‑year as Colli‑Pee launch/prep spending tapered; company cites disciplined cost controls and insourcing manufacturing to support margins.
Path to Operational Cash Flow Breakeven
Operating cash flow was negative $9.9M in Q2 but management reiterates expectation to reach operating cash flow breakeven entering 2027, supported by launch contributions and efficiency initiatives.
DE:EP3 Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed